Navigation

Brietal

Brietal - General Information

An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia.

 

Pharmacology of Brietal

Brietal, a barbiturate, is used for the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.

 

Brietal for patients

 

Brietal Interactions

Prior chronic administration of barbiturates or phenytoin (e.g. for seizure disorder) appears to reduce the effectiveness of Brevital Sodium. Barbiturates may influence the metabolism of other concomitantly used drugs, such as phentyoin, halothane, anticoagulants, corticosteroids, ethyl alcohol, and propylene glycol-containing solutions.

 

Brietal Contraindications

Brevital Sodium is contraindicated in patients in whom general anesthesia is contraindicated, in those with latent or manifest porphyria, or in patients with a known hypersensitivity to barbiturates.

 

Additional information about Brietal

Brietal Indication: Indicated for use as an intravenous anaesthetic.
Mechanism Of Action: Brietal binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Methohexital
Synonyms: Methodrexitone; Methohexitone
Drug Category: Anesthetics; Barbiturates
Drug Type: Small Molecule; Approved

Other Brand Names containing Methohexital: Brevital; Brevital sodium; Brietal;
Absorption: The absolute bioavailability following rectal administration of methohexital is 17%.
Toxicity (Overdose): The onset of toxicity following an overdose of intravenously administered methohexital will be within seconds of the infusion. If methohexital is administered rectally or is ingested, the onset of toxicity may be delayed. The manifestations of an ultrashort-acting barbiturate in overdose include central nervous system depression, respiratory depression, hypotension, loss of peripheral vascular resistance, and muscular hyperactivity ranging from twitching to convulsive-like movements. Other findings may include convulsions and allergic reactions. Following massive exposure to any barbiturate, pulmonary edema, circulatory collapse with loss of peripheral vascular tone, and cardiac arrest may occur.
Protein Binding: 73%
Biotransformation: Metabolism occurs in the liver through demethylation and oxidation. Side-chain oxidation is the most important biotransformation involved in termination of biologic activity.
Half Life: 5.6 ± 2.7 minutes
Dosage Forms of Brietal: Injection, powder, for solution Intramuscular
Injection, powder, for solution Intravenous
Chemical IUPAC Name: 5-hex-3-yn-2-yl-1-methyl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
Chemical Formula: C14H18N2O3
Methohexital on Wikipedia: https://en.wikipedia.org/wiki/Methohexital
Organisms Affected: Humans and other mammals